New treatment options are critical, as approximately half of all people with heart failure die within five years of diagnosis. Heart failure accounts for more than one million hospitalisations a year in the US
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants
TSC causes epilepsy in up to 85 % of patients, and up to 60 % of those patients do not respond to standard anti-seizure medicines
The study was conducted in patients with mild to moderate COVID-19
The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.
Bharat Biotech expects to share further details of the trial results as additional data become available.
Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.
Subscribe To Our Newsletter & Stay Updated
